-+ 0.00%
-+ 0.00%
-+ 0.00%

Hutchmed Drugs Qualify for China's Reimbursement List With Expanded Coverage

MT Newswires·11/16/2026 01:24:56
Listen to the news
01:24 AM EST, 11/16/2026 (MT Newswires) -- Hutchmed (China)'s (HCM.L) Elunate, Orpathys, and Sulanda retained their spots in China's updated national reimbursement drug list under their existing multi-year agreements, with expanded coverage for new indications. Effective Jan. 1, 2027, Elunate will also be cleared for reimbursement for certain patients with locally advanced or metastatic renal cell carcinoma, according to a Monday release. Meanwhile, Orpathys will be newly included in the list for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor mutation-positive non-squamous non-small cell lung cancer with MET amplification after disease progression on EGFR-TKI therapy, in combination with osimertinib. The biopharmaceutical company jointly developed Orpathys with AstraZeneca (AZN.L, AZN.ST) and Elunate with Eli Lilly (LLY.F, LLY.SW).